| Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden T Foukakis, T Fornander, T Lekberg, H Hellborg, J Adolfsson, J Bergh Breast cancer research and treatment 130, 553-560, 2011 | 98 | 2011 |
| First results of the preoperative accelerated partial breast irradiation (PAPBI) trial F Van Der Leij, SCJ Bosma, MJ Van De Vijver, J Wesseling, S Vreeswijk, ... Radiotherapy and Oncology 114 (3), 322-327, 2015 | 80 | 2015 |
| Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial T Hatschek, T Foukakis, J Bjöhle, T Lekberg, H Fredholm, E Elinder, ... JAMA oncology 7 (9), 1360-1367, 2021 | 49 | 2021 |
| Five-year results of the preoperative accelerated partial breast irradiation (PAPBI) trial SCJ Bosma, F Leij, S Vreeswijk, M de Maaker, J Wesseling, ... International Journal of Radiation Oncology* Biology* Physics 106 (5), 958-967, 2020 | 48 | 2020 |
| Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab … S Kimbung, I Markholm, J Bjöhle, T Lekberg, A Von Wachenfeldt, ... International journal of cancer 142 (3), 618-628, 2018 | 46 | 2018 |
| The impact of a hepatobiliary multidisciplinary team assessment in patients with colorectal cancer liver metastases: a population‐based study J Engstrand, N Kartalis, C Strömberg, M Broberg, A Stillström, T Lekberg, ... The oncologist 22 (9), 1067-1074, 2017 | 41 | 2017 |
| Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: results from the Swedish PREDIX HER2 trial identifying … JCS Bergh, A Andersson, J Bjohle, A Bosch, L Carlsson, AC Dreifaldt, ... Journal of Clinical Oncology 37 (15_suppl), 501-501, 2019 | 28 | 2019 |
| Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer A Matikas, J Lövrot, A Ramberg, M Eriksson, T Lindsten, T Lekberg, ... Oncoimmunology 7 (9), e1466017, 2018 | 25 | 2018 |
| Survival outcomes, digital TILs, and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial A Matikas, H Johansson, P Grybäck, J Bjöhle, B Acs, C Boyaci, T Lekberg, ... Clinical Cancer Research 29 (3), 532-540, 2023 | 24 | 2023 |
| The late effects of cancer treatment on female fertility and the current status of fertility preservation—a narrative review KA Rodriguez-Wallberg, Y Jiang, T Lekberg, HP Nilsson Life 13 (5), 1195, 2023 | 17 | 2023 |
| Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis A Marklund, T Lekberg, E Hedayati, A Liljegren, J Bergh, FE Lundberg, ... JAMA oncology 8 (10), 1438-1446, 2022 | 13 | 2022 |
| Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer A Matikas, K Wang, E Lagoudaki, B Acs, I Zerdes, J Hartman, E Azavedo, ... ESMO open 6 (2), 100076, 2021 | 11 | 2021 |
| 97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels T Hatschek, A Andersson, J Bjöhle, A Bosch, L Carlsson, AC Dreifaldt, ... Annals of Oncology 31, S49, 2020 | 6 | 2020 |
| Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 … Y Brandberg, A Andersson, J Bjohle, A Bosch, L Carlsson, AC Dreifaldt, ... Journal of Clinical Oncology 37 (15_suppl), 583-583, 2019 | 3 | 2019 |
| Markedly improved survival in patients with systemic metastatic breast cancer during a twenty year period-population based registry data from the Stockholm health care region. TG Lekherg, LE Rutqvist, J Adolfsson, J Almbrandt, H Johansson, ... BREAST CANCER RESEARCH AND TREATMENT 82, S148-S148, 2003 | 3 | 2003 |
| Abstract P5-14-05: Preoperative accelerated partial breast irradiation (PAPBI) trial: First results on acute toxicity, complications and cosmetic results F Van Der Leij, H Bartelink, E Rutgers, S Rivera, D Van Den Bongard, ... Cancer Research 73 (24_Supplement), P5-14-05-P5-14-05, 2013 | 2 | 2013 |
| First results of the PAPBI trial (Preoperative Accelerated Partial Breast Irradiation): Toxicity and cosmetic outcome PHM Elkhuizen, F van der Leij, T Lekberg, S Rivera, D van den Bongard, ... EUROPEAN JOURNAL OF CANCER 50, S102-S102, 2014 | 1 | 2014 |
| Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results … A Matikas, H Johansson, P Grybäck, J Bjöhle, T Lekberg, H Fredholm, ... Journal of Clinical Oncology 40 (16_suppl), 593-593, 2022 | | 2022 |
| One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as … Y Brandberg, T Foukakis, A Andersson, J Bjohle, A Bosch, L Carlsson, ... Journal of Clinical Oncology 38 (15_suppl), 590-590, 2020 | | 2020 |
| Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer A Matikas, J Lövrot, A Ramberg, M Eriksson, T Lindsten, T Lekberg, ... Annals of Oncology 28, v68, 2017 | | 2017 |
